Paper Details

  1. Home
  2. Paper Details

Pharmacovigilance of unlicensed cannabidiol in European countries.

Author: AmmendoliaIlaria, CalapaiFabrizio, CalapaiGioacchino, CardiaLuigi, ChinouIoanna, CurròMariaconcetta, EspositoEmanuela, MannucciCarmen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The study analyzed serious adverse reactions (SARs) to unlicensed cannabidiol (CBD) products. SARs were more frequent in men and adults, with mental disorders, hepatic disorders, and aggravation of pre-existing epilepsy being the most common adverse effects. The study suggests that precautions and appropriate surveillance of adverse effects should be taken when unlicensed CBD is used.
Paper Details　
Original Abstract of the Article :
Cannabidiol (CBD) is a multitarget agent possessing anti-inflammatory and antioxidant properties. Unlicensed CBD gained public favor for the care of general health and well-being as well as to get comfort from inflammatory complaints, pain, anxiety, mood, and sleep disorders. Safety profile of unlic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/ptr.8028

データ提供：米国国立医学図書館（NLM）

The Safety of Unlicensed Cannabidiol in Europe

The world of medicine is constantly evolving, and with it, the use of new substances. Cannabidiol (CBD), a compound found in cannabis, is gaining popularity for its potential health benefits. However, the use of unlicensed CBD products raises concerns about safety and potential adverse reactions. This research delves into the world of pharmacovigilance, analyzing reported adverse reactions to unlicensed CBD products in Europe. It's like exploring a vast desert of knowledge, uncovering hidden truths about the potential risks and benefits of this increasingly popular substance.

A Closer Look at the Data

The study, published in the journal Cannabis and Cannabinoid Research, analyzed data from EudraVigilance, a European Medicines Agency database that collects reports of suspected adverse drug reactions. They found that serious adverse reactions to unlicensed CBD products accounted for 18.9% of all reported events. This discovery highlights the need for caution, especially for those considering using unlicensed CBD products.

Navigating the Desert of CBD Safety

Remember, just like navigating a vast desert, it's important to have reliable resources and be aware of potential dangers. This research emphasizes the need for further studies to thoroughly evaluate the safety of unlicensed CBD products. It's crucial to consult with healthcare professionals to weigh the potential benefits against the risks and to ensure informed decision-making.

Dr.Camel's Conclusion

The use of unlicensed CBD products is like a camel traversing an unexplored desert – exciting, but potentially risky. The research sheds light on the importance of careful monitoring and understanding potential risks associated with unlicensed CBD products. While CBD offers exciting possibilities for health and well-being, it's vital to stay informed and make responsible choices based on reliable scientific evidence. Always consult your healthcare provider for personalized advice and guidance.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-06
Further Info :

Pubmed ID

37800192

DOI: Digital Object Identifier

10.1002/ptr.8028

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.